Search
Trimethaphan
go.drugbank.com/drugs/DB01116ApprovedInvestigationalA nicotinic antagonist that has been used as a ganglionic blocker in hypertension, as an adjunct to anesthesia, and to induce hypotension during surgery.
Technetium Tc-99m red blood cells
go.drugbank.com/drugs/DB09493ApprovedWithdrawnTechnetium Tc-99m red blood cells is a radiopharmaceutical diagnostic agent that is intravenously administered to be used in blood pool imaging, including cardiac first pass and gated equilibrium imaging and for detection of sites of gas...
Ketazolam
go.drugbank.com/drugs/DB01587ApprovedWithdrawnKetazolam is a benzodiazepine derivative with anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant activity. Ketazolam is not approved in Canada or America.
Succimer
go.drugbank.com/drugs/DB00566ApprovedInvestigationalA mercaptodicarboxylic acid used as an antidote to heavy metal poisoning because it forms strong chelates with them.
Gallium nitrate
go.drugbank.com/drugs/DB05260ApprovedInvestigationalGallium nitrate is a nitrate salt of DB14524, a heavy metal that has been used as a diagnostic agent. Gallium nitrate is reported to possess antiresorptive and hypocalcemic effects on bone. GANITE, a product of gallium nitrate previously...
Denileukin diftitox
go.drugbank.com/drugs/DB00004ApprovedInvestigational[A264349, L51254] Denileukin diftitox was originally approved by the FDA in 1999 for the treatment of cutaneous T-cell lymphoma (CTCL),[A264339, L51264] making it the first fusion protein cytotoxin
Pipamperone
go.drugbank.com/drugs/DB09286InvestigationalIt was developed by Janssen Pharmaceutica in 1961 and started its first round of clinical trials in 1963 [L1514, L1518].
Lunsotogene parvec
go.drugbank.com/drugs/DB18278ApprovedInvestigational[L56137] It acts by delivering functional copies of the human _OTOF_ gene specifically to inner hair cells via an engineered hair-cell-specific Myo15 promoter, which restores essential synaptic transmission
Vonoprazan
go.drugbank.com/drugs/DB11739ApprovedInvestigationalUnlike proton-pump inhibitors, PCABs are not affected by CYP2C19 genetic polymorphisms and do not require acid-resistant formulations.